Clinical Trial Update: Gemigliptin-Rosuvastatin Fix-dose Combination Phase 3(BALANCE) [Phase 3]

View source ↗

Summary

The document reports completion of a Phase 3 BALANCE study evaluating a fixed-dose combination of gemigliptin and rosuvastatin for patients with Type 2 diabetes…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia
• Type 2 Diabetes Mellitus

Drugs mentioned

• Gemigliptin (gemigliptin)
• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: LG Life Sciences | Conditions: Type 2 Diabetes, Dyslipidemia | Phase 3 | Status: COMPLETED